Status:
COMPLETED
Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
Lead Sponsor:
Pfizer
Conditions:
Carcinoma, Renal Cell
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
A phase II study to allow patients with advanced kidney cancer access to sunitinib malate treatment and to find out the good and bad effects of taking 37.5 mg sunitinib malate in a continuous daily re...
Eligibility Criteria
Inclusion
- Advanced kidney cancer
Exclusion
- Previous treatment for kidney cancer, except surgical removal of kidney tumor
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00338884
Start Date
September 1 2006
End Date
April 1 2009
Last Update
August 31 2012
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Córdoba, Córdoba Province, Argentina, X5000AAI
2
Pfizer Investigational Site
Rosario, Santa Fe Province, Argentina, (2000)
3
Pfizer Investigational Site
Buenos Aires, Argentina, 1431
4
Pfizer Investigational Site
Adelaide, South Australia, Australia, 5000